New financing led by Bessemer Venture Partners will expand go-to-market operations and accelerate product roadmap

ANN ARBOR, Mich., May 16, 2024 — Voxel51, the leader in visual AI, today announced that it has closed a $30M Series B funding round. The round was led by Bessemer Venture Partners, with participation from new investor Tru Arrow Partners and existing investors Drive Capital, Top Harvest Capital, Shasta Ventures and ID Ventures. Voxel51 will use this funding to scale up its go-to-market organization, expand its community, invest in AI research and accelerate its roadmap to meet the growing market demand for solutions that unlock the value of visual AI.

Voxel51 was founded by a team of machine learning and computer vision experts to help address the distressing failure rate of AI projects. While investments in AI have exploded, a recent article in Harvard Business Review reported that the failure rate of AI projects is estimated to be as high as 80%. With visual data, such as the image and video data that already make up over 60% of all data traffic, becoming an increasingly important part of AI projects, the complexity and difficulty of building successful AI applications only increases. All too often, the culprit behind these failures is the struggle to put visual data to work in building production-ready AI models and applications—today’s fragmented, inflexible tools and clunky manual processes lead to lengthy development cycles and painful errors in production.

Voxel51 offers the antidote to those headaches, transforming the way that AI engineers and teams build visual AI. Voxel51 provides the leading refinery for data + models, where AI builders can simplify and automate their workflows to explore, visualize, curate and test datasets and put them to use to build models and applications. Tens of thousands of AI builders rely on Voxel51’s open source FiftyOne and enterprise FiftyOne Teams offerings to build production-ready visual AI that is dramatically more accurate and robust, improving team productivity by up to 50% and model accuracy by up to 30%. Innovative organizations including LG Electronics, Berkshire Grey, Precision Planting, RIOS Intelligent Machines and Forsight use Voxel51 solutions to help them build innovative visual AI solutions that improve product quality, ensure safety and increase efficiency.

“Traditional enterprises have increasingly sophisticated AI and ML teams with complex workflows that still include painful manual processes,” said Lindsey Li, investor at Bessemer Venture Partners. “As soon as Brian described his vision at Voxel51, we could see the platform’s role as core enterprise AI infrastructure of the future. We’ve been impressed by the entire team and their elegant and differentiated solution as a true orchestration layer for customers to build AI-forward and AI-native applications, faster and more easily. We are thrilled to partner with the team to build and scale their continued success.”

“No one would build and tune a race car on a grass field and expect to win a Formula 1 race,” said Brian Moore, CEO and co-founder of Voxel51. “Yet, organizations building visual AI are all too often forced to build and fine-tune models with mislabeled, inadequate and under-representative data and then hope for success in production. We’re helping our customers and community build better AI applications by bringing their models and data together in one place, and we’re thrilled to have the support of great investors to accelerate our mission to make visual AI a reality.”

This new fundraising round is a milestone enabled by the momentum demonstrated since the close of its Series A funding round:

• 4x increase in community membership and engagement
• 6x growth to over 2 million downloads of the open source FiftyOne project
• 10x increase in ARR for the commercial FiftyOne Teams offering

That growth has been supported by continued innovation delivered by the Voxel51 team, including the following recent highlights:

• Integration of FiftyOne and NVIDIA Omniverse to help autonomous vehicle developers create, curate, and visualize robust synthetic training data to maximize AI model performance
• Native vector search integrations with engines including Pinecone, MongoDB, Redis, Qdrant and more to enable fast, easy search through billions of images
• Introduction of VoxelGPT, a natural-language interface to FiftyOne that makes it possible for users to leverage large language models (LLMs) to rapidly and easily gain insights about visual data

“FiftyOne Teams is critical to getting our AI models into the real world,” said Matt Shaffer, VP of Artificial Intelligence and Co-Founder at RIOS Intelligent Machines. “It’s the hub that powers our AI workflows, from data management to model refinement, enabling us to deliver AI-powered robotics into production lines rapidly and reliably to help our customers improve food packaging, reduce waste, and improve safety for any person on the factory floor.”

To learn more:

About Voxel51

Voxel51 is helping organizations make visual AI a reality. Our open source and commercial software enables teams to build high-quality datasets and computer vision models that power leading machine learning and artificial intelligence applications. Tens of thousands of engineers and scientists have integrated open source FiftyOne into their workflows, and enterprise customers spanning from automotive, robotics, security and retail to healthcare rely on FiftyOne Teams to securely collaborate on datasets and models. We’re building a fully-remote team of exceptional and diverse people who want to bring visual AI to life. To learn more, visit voxel51.com.

SOURCE Voxel51

Precision medicine biotechnology company for obesity secures additional institutional capital from prominent industry leaders to expand the use of its novel phenotyping test and advance clinical research in weight loss treatment.

MENLO PARK, Calif., May 16, 2024 — Phenomix Sciences (Phenomix), a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, has secured $5.5 million in Series A funding from new investors, DexCom, Inc. and Labcorp, and existing investors, including Health2047. The company has also been awarded a $2.3 million Phase II Small Business Innovation Research (SBIR) Grant through the National Institutes of Health (NIH).

“As leaders in their respective fields of lab testing and patient empowerment, we are excited to add DexCom and Labcorp as investors as we continue to scale our company. In addition, Labcorp will provide laboratory testing services,” said Mark Bagnall, CEO of Phenomix. “After more than a decade of research from our founders, we are thrilled the wider industry is also seeing the need to treat the obesity epidemic seriously with clinically focused solutions. The substantial financial backing for Phenomix’s clinically validated precision obesity programs from prominent companies in the health industry underscores the importance precision medicine is poised to have on combating obesity.”

This capital will accelerate the commercialization and adoption of the MyPhenome™ test in the obesity specialist market and the wider industry. The MyPhenome test equips physicians with essential tools to develop effective treatment plans including lifestyle and diet intervention as well as medication and/or procedure recommendations. The MyPhenome test identifies obesity phenotypes, subtypes of the disease caused by the interaction of a patient’s genes and the environment. These phenotypes include Hungry Gut, Hungry Brain and Emotional Hunger. As demonstrated by Phenomix’s co-founders and Mayo Clinic physicians, Andres Acosta, M.D. Ph.D. and Michael Camilleri, M.D. D.Sc., obesity phenotypes help explain why people exhibit varying responses to different treatments.

The funds will also enable the company to develop and launch additional phenotyping tests, continue to support clinical studies and patent novel insights, and further strategic relationships with pharmaceutical companies and health care providers.

The SBIR grant allows the company to perform additional clinical studies demonstrating the value of obesity precision medicine. The sizable award from the NIH is a testament to the importance of this work on the future of obesity treatment as well as the esteemed reputation of Phenomix’s founders and significance of their prior studies. Specifically, the grant will fund a prospective study of the MyPhenome test and further prove its accuracy in predicting obesity treatment response.

The company recently launched its new three-in-one MyPhenome obesity phenotyping test,^, including Hungry Gut, Hungry Brain and Emotional Hunger, currently in use by U.S. providers. For more information, visit www.phenomixsciences.com.

About Phenomix Sciences
Phenomix Sciences is a precision obesity biotechnology company on a mission to conquer obesity globally through the use of our proprietary genetic tests, unique data sets, and advanced analytics. Mayo Clinic physicians, scientists, and researchers, Andres Acosta, M.D. Ph.D., and Michael Camilleri, M.D. D.Sc., founded the company after 10 years of rigorous clinical research focused on uncovering the pathophysiology behind the variability in response to obesity treatments. Phenomix believes that the key to understanding obesity is its unprecedented access to clinical and molecular information throughout all stages and phenotypes of the disease. Phenomix leverages data intelligence for yielding better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients. For more information, please visit www.phenomixsciences.com.

Media Contact:
[email protected] 

SOURCE Phenomix Sciences

SYDNEY, May 16, 2024 — Australian music licensing startup, Melodie (www.melod.ie), has just secured $1M in fresh funds, ahead of a strategic capital raise planned for 2025.

As of 2024, this puts the company’s total funding at just under $3M from investors including early Atlassian employee and Code Barrel founder Nick Menere, and Peter Strain, co-owner of The Drop Festival.

The company’s continued growth and success has been acknowledged by The CEO Magazine where Evan Buist, Melodie’s Founder and Managing Director, was recently awarded ‘Highly Commended Entrepreneur of the Year’, ahead of Melodie taking out the prestigious ‘Product of the Year‘ award (Audio Production, Processing and Networking) at NAB Show in Las Vegas last month, as well as Acquisition International’s Global Excellence Award for ‘Music Platform of the Year 2024 – APAC’.

Melodie was founded in November 2017. Since then, from an investor’s perspective Melodie’s core numbers have been growing exponentially. In fact, they have had an impressive 96-229% YoY increase in revenue over each of the past three years, which includes snowballing broadcast royalty income and recurring revenue from creators, brands, broadcasters, production companies and API users (such as the US-based GoDaddy Studio).

Investors are paying attention, as Melodie just announced a convertible note bridging round ahead of a larger strategic equity raise planned for 2025. With $1M already committed, there is clearly strong investor confidence in the company’s continued growth.

Melodie’s Founder, Evan Buist, said the bridge round would help to fuel strategic partnerships and international growth, ahead of setting up Melodie’s first European office in France this year.

“As we mark our sixth year of operation, we are building closer relationships with our partners, and broadening our global presence. Three of the world’s four largest royalty markets are France, the UK and Germany. With more than 20 million minutes of our music now broadcast on FTA and VOD platforms in Australia alone, we are looking to replicate that success in key European markets, leveraging data to create long-term, powerful strategic alliances,” Buist claims.

Melodie will be exhibiting at IBC Amsterdam in September, and MIPCOM Cannes in October. Showcasing a catalogue that now sits at over 25,000 exclusive, high-quality tracks created by a roster of award-winning composers and independent artists from all around the world.

Melodie’s purpose of supporting a creative community remains at its core: every time a piece of music is downloaded at Melodie, an artist gets paid. Melodie continues to create income for countless independent musicians, in a way that places value on their creativity and acknowledges the arts as an income-generating industry.

“Melodie has demonstrated exceptional growth and innovation in the music licensing industry and we are proud to support them as they continue to revolutionize the music ecosystem and create significant value for both creators and investors,” shared Aly Madhavji, Managing Partner at Blockchain Founders Fund.

About Melodie
Melodie Music is an Australian company that provides a simple solution for content creators seeking to find and license high-quality music for their projects. With Creator, Pro and Enterprise subscription options, their exclusive and meticulously curated catalogue of original music is accessible through an online search platform equipped with AI-powered search tools. Founded by composers, musicians and sound designers with first-hand experience of the crucial role music plays in storytelling, Melodie delivers an intuitive, user-friendly music licensing platform that caters to the needs of content creators, while supporting the growth of the music creators themselves. Learn more at www.melod.ie

Melodie Contact Details:
●  Contact: Kat Tame, Marketing Manager
●  Email: [email protected]
●  Number: +61 (0)415 562 574
●  Website: https://melod.ie/

Download Images here.

SOURCE Melodie

New leaders bring deep industry expertise from former roles at Kyruus Health, Health Catalyst, Glytec, HubSpot, and Veeva

NEWTON, Mass., May 16, 2024 — Manifold, an AI-powered clinical research platform, today announced the expansion of its leadership team with veterans of the technology and healthcare industries. Following its $15 million Series A fundraising round, the expanded team will accelerate Manifold’s ability to automate the manual work of clinical study and data operations alongside its customers, including Indiana University Melvin and Bren Simon Comprehensive Cancer Center and Winship Cancer Institute of Emory University.

The following executives are joining Manifold to accelerate the company’s growth:

• Chris McMahon joins as Chief People Officer, after previously leading the People function at Kyruus Health and Turbonomic through aggressive periods of growth and expansion. Chris will be responsible for developing and recruiting talent, building culture, and overseeing people operations.
• Alex Akers joins as Vice President, Growth, having previously served as VP, Sales at Health Catalyst as a part of their remarkable growth story, and before that as Director, Strategy and Institutional Partnerships at Grand Rounds. Leveraging his deep expertise in strategy and market development, Alex will spearhead growth and expansion efforts across key cancer research centers.
• Danielle Kowalski joins as Vice President, Legal, bringing extensive commercial go-to-market and compliance experience to Manifold after spending over 11 years at HubSpot where she most recently served as VP & Deputy General Counsel in their Legal & Compliance function.
• Megan Ahigian joins as Senior Director of Product and Partnerships, bringing experience building data-rich products across Healthcare and IT Infrastructure during periods of rapid growth. Megan previously served as VP, Product at Glytec and VP, Product at Kyruus Health.
• Taylor Gleason joins as Senior Director of Marketing, bringing deep knowledge of full-funnel marketing strategy in the healthcare technology space, following marketing roles at Kyruus Health, Press Ganey, Amwell, Boston Children’s Hospital and Cigna.

Manifold also welcomes two go-to-market veterans to its advisory team:

• Mike Longo joins as a go-to-market advisor, having previously served as the Vice President, North America R&D Sales at Veeva and an integral part of the leadership team that grew Veeva from its startup stage to over $1 billion in revenue.
• Chris Reisig also joins as a go-to-market advisor and brings extensive advisory experience with early-stage technology companies, having led the sales function at companies like Dyn, Turbonomic, Veracode and Endeca.

“We’re thrilled to welcome some of the industry’s strongest leaders to help us transform clinical study and data operations with our AI-powered platform,” said Vinay Seth Mohta, CEO and Co-Founder of Manifold. “Our team will be crucial to growing our partnerships and expanding our solutions – achieving our vision of making it ten times faster and one-tenth the cost to carry out modern studies and analytics.”

The growth and diversity of healthcare data is surpassing legacy data management and analytic tools as well as manual processes in clinical research. With Manifold, for the first time, clinical research teams have an advanced, AI-powered, purpose-built platform that makes it possible to enroll and engage study participants, harmonize and curate longitudinal data, find and analyze multimodal datasets, and collaborate securely across organizations — all in one easy-to-use platform.

About Manifold
Manifold is an AI-powered clinical research platform. We streamline the manual workflows of modern study and data management, enabling researchers to do more high-impact research and collaborations with fewer resources. Manifold works with research organizations across the country such as Indiana University Melvin and Bren Simon Comprehensive Cancer Center and Winship Cancer Institute at Emory University. Our vision is to make it ten times faster and one-tenth the cost to conduct modern research studies that unlock insights never-before possible. For more information, visit us here, or follow us on LinkedIn.

Media Contact: Kayli Watson, [email protected]

SOURCE Manifold

MORRISVILLE, N.C., May 16, 2024 — Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announced that it has closed on a new $60 million credit facility. This significant investment, of which an initial $42.5 million was funded at closing, will be utilized to fuel the company’s growth initiatives and expand its research and development efforts to further enhance its metabolomics platform. The investment will also support the company’s global expansion plans, including market penetration initiatives and strategic partnerships.

The financing was led by Trinity Capital, Inc., and enabled early retirement of the Company’s previous $35 million debt facility. It follows a $25 million equity financing that closed in January of 2023.

“We are extremely pleased to announce this successful financing, marking a significant milestone for Metabolon. This infusion of additional capital and robust process leading up to it underscore the strong investor confidence in Metabolon’s vision, capabilities, and market potential within the multiomics and metabolomics industry” said Rohan (Ro) Hastie Chief Executive Officer at Metabolon. “As the life sciences embrace a sophisticated multiomics paradigm, Metabolon is emerging as an industry benchmark and an essential catalyst toward achieving true precision medicine. This investment will enable us to accelerate growth, drive innovation, and further solidify our position as a leader in the metabolomics space.”

“Despite relatively challenging capital markets environment, this investment of non-dilutive growth capital, combined with the equity round before it, are proof that top-performing companies like Metabolon continue to attract funding. We are thrilled to have this top-tier investor backing us, enabling us to advance scientific research, drive breakthrough discoveries, and further develop our technology as we bring market-leading metabolomics and bioinformatics solutions to the multiomics community,” said Gerry Haines, Chief Financial Officer at Metabolon.

“We are excited to partner with Metabolon, a company that has demonstrated innovation and excellence in the life sciences sector,” said Rob Lake, Senior Managing Director, Life Sciences at Trinity. “By leveraging their cutting-edge technology and extensive experience, the team has the potential to accelerate research and we look forward to supporting the company’s ongoing growth and expansion in the industry.”

To learn more about how Metabolon deciphers thousands of discrete chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways, visit https://www.metabolon.com/.

About Metabolon
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies. With more than 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon’s Global Discovery Panel is enabled by the world’s largest proprietary metabolomics reference library. Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics supporting customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.

About Trinity Capital Inc.
Trinity (Nasdaq: TRIN), an internally managed business development company, is a leading provider of diversified financial solutions to growth stage companies with institutional equity investors. Trinity’s investment objective is to generate current income and, to a lesser extent, capital appreciation through investments, including term loans, equipment financings and equity-related investments. Trinity believes it is one of only a select group of specialty lenders that has the depth of knowledge, experience, and track record in lending to growth stage companies. For more information, please visit the Company’s website at www.trinitycap.com.

About Metabolomics
Metabolomics, the large-scale study of all small molecules in a biological system, is the only ‘omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic as well as external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.

SOURCE Metabolon, Inc.

“On behalf of Chicago’s residents and businesses, I extend a sincere welcome and congratulations to Bedrock Materials for choosing our city as the location for its Research & Development headquarters,” said Mayor Brandon Johnson. “This decision reflects the strength of Chicago’s talent pool, our esteemed research and academic institutions, and the vibrant tech ecosystem emerging here. We look forward to the positive impact Bedrock Materials will have on our city’s growing tech sector.”

Bedrock Materials specializes in producing essential materials for low-cost, eco-friendly sodium-ion batteries. These batteries are seen as a next-generation alternative to lithium-ion versions, utilizing affordable, widely available materials. Last month, the company began R&D scale production of battery precursor materials at its facility in Near West Chicago. Plans are underway to open a larger, permanent site later this year.

Concurrent with this strategic move, Bedrock Materials also secured an incentives package from the Illinois state government under the Reimagining Electric Vehicles in Illinois Act, contingent upon achieving specific job creation and capital investment targets.

“Illinois is home to one of the most robust EV ecosystems in the nation, and I’m thrilled to welcome Bedrock Materials to our great state,” said Governor JB Pritzker. “Their research and development headquarters will join our growing EV supply chain, bringing innovation and job creation to our EV economy.”

The company’s decision to locate in Chicago was driven in large part by the abundance of strong materials science research institutions in the area, including Northwestern University, University of Chicago, University of Illinois, and Illinois Institute of Technology. Moreover, Argonne National Laboratory, in Lemont, Illinois, is a key leader in the development of sodium-ion batteries.

“The choice to come to Chicago was an easy one. There is arguably one active laboratory in America that has produced a successful automotive battery chemistry, and it’s here” said Spencer Gore, CEO of Bedrock Materials, “Argonne National Laboratory wrote the book on modern sodium-ion technology. Today, pulling on the deep regional talent pool they have built, we are excited to perfect and scale it.”

Professor Shirley Meng of the University of Chicago commented, “It is truly exciting that the State of Illinois can attract startup companies like Bedrock Materials to be part of the clean tech community. The innovation ecosystem is growing, and we look forward to collaborating with and supporting startups.” Professor Meng is also the Chief Scientist of the Argonne Collaborative Center for Energy Storage Science.

The $9 million financing round was led by Trucks Venture Capital, Refactor Capital, and Version One Ventures. Additional investment was provided by Hanover Technology Investment Management, SpaceCadet Ventures, Brainstorm Capital, Evergreen Climate Innovations, Expansion VC, Climate Capital, Quest Venture Partners, Meliorate Partners, Valia Ventures, Ritual Capital, and several individual angel investors with strong ties to the electric vehicle and battery industries.

Founded in 2023 by Rafael Vila, CTO and a distinguished battery scientist from Stanford University, and CEO Spencer Gore, a seasoned battery industrialist with experience at Tesla and Enovix, Bedrock Materials boasts a management and advisory team composed of current and former executives from Tesla, Volkswagen, General Motors, Samsung, Panasonic, QuantumScape, Sila Nanotechnologies, Enovix, and Apple.

About Bedrock Materials

Bedrock Materials is a battery technology startup that manufactures critical input materials for sodium-ion batteries, which promise to offer a cost-effective and environmentally sustainable alternative to traditional lithium-ion batteries. The company aims to leverage the rich resources and strategic positioning of Chicago to lead the next wave of battery technology innovation.

For additional information, please contact: [email protected]

SOURCE Bedrock Materials, Inc.

PHOENIX, May 16, 2024 — Trinity Capital Inc. (NASDAQ: TRIN) (“Trinity”), a leading provider of diversified financial solutions to growth-stage companies, today announced the commitment of $60 million in growth capital to Metabolon, a global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications.

Metabolon develops scientific, technological, and bioinformatics techniques to measure inputs from internal and external factors such as health, disease, nutrition, microbiome, medication, and environmental exposure, to help answer scientific questions about health and disease. Metabolon’s customizable metabolomics solutions support research in the biopharma, population health, consumer products, agriculture, wellness, academic, and government sectors, across the research continuum.

“We are excited to partner with Metabolon, a company that has demonstrated innovation and excellence in the life sciences sector,” said Rob Lake, Senior Managing Director, Life Sciences at Trinity. “By leveraging their cutting-edge technology and extensive experience, the team has the potential to accelerate research and we look forward to supporting the company’s ongoing growth and expansion in the industry.”

This new growth capital will allow Metabolon to expand its research and development efforts to further enhance its metabolomics platform. The investment will also support the company’s global expansion plans, including market penetration initiatives and strategic partnerships. 

“We are extremely pleased to announce this successful financing with Trinity, marking a significant milestone for Metabolon. This infusion of additional capital and robust process leading up to it underscore the strong investor confidence in Metabolon’s vision, capabilities, and market potential within the multiomics and metabolomics industry” said Rohan (Ro) Hastie Chief Executive Officer at Metabolon. “As the life sciences embrace a sophisticated multiomics paradigm, Metabolon is emerging as an industry benchmark and an essential catalyst toward achieving true precision medicine. This investment will enable us to accelerate growth, drive innovation, and further solidify our position as a leader in the metabolomics space.”

About Trinity Capital Inc.
Trinity (Nasdaq: TRIN), an internally managed business development company, is a leading provider of diversified financial solutions to growth stage companies with institutional equity investors. Trinity’s investment objective is to generate current income and, to a lesser extent, capital appreciation through investments, including term loans, equipment financings and equity-related investments. Trinity believes it is one of only a select group of specialty lenders that has the depth of knowledge, experience, and track record in lending to growth stage companies. For more information, please visit the Company’s website at www.trinitycap.com.

About Metabolon
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies. With more than 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon’s Global Discovery Panel is enabled by the world’s largest proprietary metabolomics reference library. Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, supporting customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.

SOURCE Trinity Capital Inc.

Football (U.S. soccer) is the world’s most popular sport, and fandom has grown 60% in the U.S. over the past decade.

The iconic football shirt connects people to the sport’s unique culture, from fans to fashion enthusiasts and celebrity influencers globally.

With the largest collection of new and hard-to-find authentic football shirts available for sale in the world, and millions of items shipped across more than 100 countries, Classic Football Shirts is the category leader.

MANCHESTER, England and LOS ANGELES, May 16, 2024 — Classic Football Shirts, the global hub to buy authentic football shirts, and The Chernin Group (“TCG”), a multi-stage investment firm known for building and growing consumer businesses, today announced an investment from TCG that will fuel aggressive and immediate global expansion plans. Concentrating on North America, one of the brand’s fastest-growing markets that represents just 15 percent of the overall business today, TCG’s investment underscores the significant market opportunity tied to the rising global interest in football culture.

There are 3.5 billion global football fans in the world and fandom is up 60% in the U.S. over the last decade as major European domestic leagues are aired on U.S. TV networks, shows like Ted Lasso and Welcome to Wrexham have streamed into family rooms, fashion designers have given a nod to football style in collections, and celebrity superstars have been photographed wearing the football shirts. With the expansion of the MLS, success of NWSL and major global football events like the 2024 Copa America, 2025 FIFA Club World Cup, 2026 FIFA World Cup and the 2028 Olympics, fandom is only expected to grow even more over the next 10 years. As the game’s domestic fan base continues to rise, so has consumer demand for football commerce and apparel.

“Each football shirt tells a unique story and represents the history, culture, style – and the nostalgia of the game,” said Classic Football Shirts founder and CEO, Doug Bierton. “It’s a passion and obsession for the sport, from our team and our customers, that built the business to where it is today. It’s exciting to think about how we’ll connect with millions more around the world over a shared love of football.”

Founded in 2006 in Manchester, UK by Doug Bierton and Matthew Dale – and later joined by co-founder Gary Bierton, Classic Football Shirts has thrived as a self-funded, fast-growing enterprise that’s been profitable since its inception. The company boasts a staggering collection of rare vintage, match-worn, and current season styles that cater to a diverse community of football aficionados, collectors, and streetwear enthusiasts worldwide. It has a thriving community both on and offline, with stores in London and Manchester, UK, millions of social followers, and customers in over 100 countries. They have classic football shirts listed from thousands of clubs, countries and players, and over 6,700 unique or match-worn shirts housed in ‘The Vault‘, a climate-controlled storage area for special pieces that are not yet available to the public.

“The Classic Football Shirts team has built an incredible business,” said TCG partner, Greg Bettinelli, an early investor in popular consumer marketplaces, including GOAT and thredUP while at his previous firm, Upfront Ventures. “They have an incredible selection of football shirts for fans all over the world, unparalleled industry knowledge and a true passion for the sport. Everyone who comes to Classic Football Shirts knows they will find their favorite club, country or player and trusts that the shirt they buy will be 100% authentic, which is why so many come back again and again. We are looking forward to working with Doug, Matt, Gary and the rest of the team to build on their success through the expansion of its audience, assortment and new geographies.”

TCG invested $38.5M of growth equity capital into Classic Football Shirts and is the only major outside investor. With this investment, Classic Football Shirts will continue on its path to being the global destination for authentic football shirts and cultivate a community of fans and fashion enthusiasts through a shared love of the unique shirts.

In addition, Cormac Barry, a senior executive with over 25 years’ experience in online B2C, online B2B and retail across multiple sectors including sports and travel, has joined Classic Football Shirts as Executive Chairman.

Coinciding with this announcement today is the opening of Classic Football Shirts’ latest retail experience in New York City. The store at 323 Canal Street offers enthusiasts a glimpse into football’s rich heritage through a curated collection of both classic and current shirt styles. The event precedes the forthcoming launch of permanent stores in New York and Los Angeles later this year. For further details, visit www.classicfootballshirts.co.uk.

About Classic Football Shirts

Classic Football Shirts is the global hub to buy authentic football shirts. The company was founded in 2006 in Manchester, UK by Doug Bierton and Matthew Dale – and later joined by Gary Bierton, who share a love of the sport and its culture. Classic Football Shirts has the largest collection of authentic football shirts in the world, from timeless classics to elusive vintage finds and some of the game’s most iconic shirts. A dedication to curation and authentication, deep knowledge of the history, and a genuine passion for the sport has been the driving force behind Classic Football Shirts’ success and rapidly growing global customer base. Explore the extensive collection of football shirts and join the community of fans and enthusiasts at www.classicfootballshirts.co.uk.

About TCG

Founded by Peter Chernin, Jesse Jacobs, and Mike Kerns, The Chernin Group (TCG) is a multi-stage investment firm dedicated to building enduring consumer businesses. TCG partners with exceptional management teams to grow market-leading businesses in categories of consumer passion such as sports, commerce, gaming, and health and wellness. The firm leverages decades of operating experience and deep connectivity to the media and technology ecosystem in service of its portfolio companies. Investments have included Action Network, Barstool Sports, Cars & Bids, Collectors, Crunchyroll, Epic Gardening, Meateater, Oura, Premier Lacrosse League, Scopely and Unrivaled Sports. Learn more at https://tcg.co/.

Note for editors: 

Press kit with images can be found here.

Contact:

[email protected] 

SOURCE Classic Football Shirts

SINGAPORE, May 16, 2024 — OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, has issued updates for May 16, 2024.

OKX Ventures Ranked as #1 Crypto Venture Capital Investor in Q1 2024 with 31 Deals

OKX Ventures today announced that it has secured its position as the number one crypto venture capital investor in Q1 2024, closing a remarkable 31 deals*. Its top investment areas for Q1 focus on infrastructure, AI and DeFi. Notable projects include the Bitcoin EVM-Compatible Rollup, B² Network, and FLock.io, a decentralized and permissionless platform for AI models and dApps.

This milestone further cements OKX Ventures’ commitment to investing in the future of blockchain and Web3 innovation, reinforcing its dedication to the sector. OKX Ventures’ consistent and substantial capital investment shows its strong confidence in the growth and potential of the crypto and Web3 space. In 2023, the firm invested USD 50 million in crypto and Web3 projects.

OKX Ventures Founder Dora Yue said: “Our diverse investment portfolio, with a focus on the rapidly evolving Web3 infrastructure, AI and DeFi sectors, positions us at the forefront of supporting these groundbreaking technologies. As the crypto space continues to mature and gain mainstream adoption, we remain dedicated to driving innovation, fostering growth, and empowering projects that will shape the future of the digital economy.”

*Source: CryptoRank

For further information, please contact:
[email protected]

About OKX Ventures

OKX Ventures is the investment arm of the second-largest crypto exchange by trading volume and Web3 technology company OKX, focusing on exploring the best blockchain projects on a global scale and supporting cutting-edge blockchain technology innovation.

Find out more about OKX Ventures here.

Disclaimer

SOURCE OKX Ventures